Vicente Carrillo 'El Viceroy' faces October hearing in NY as plea deal talks continue
Translated from Spanish, summarized and contextualized by DistantNews.
At a glance
- Mexican drug trafficker Vicente Carrillo, known as "El Viceroy," will have a pre-trial hearing on October 20 in New York.
- Negotiations for a potential plea deal between Carrillo's defense and the U.S. Attorney's Office are ongoing.
- Carrillo faces charges including continuing criminal enterprise, conspiracy to import cocaine, and money laundering.
Mexican drug trafficker Vicente Carrillo, also known as "El Viceroy," is scheduled for a pre-trial hearing on October 20 in New York. This date was set by federal Judge Joan Azrack after prosecutors and Carrillo's defense team requested more time to finalize negotiations for a potential plea agreement.
During a technical hearing, both sides reported "productive" progress in their discussions regarding a guilty plea. However, they indicated that further time was needed to work out the details. Carrillo, 63, who has been detained in Brooklyn since his extradition last year, appeared at the hearing in standard prison attire.
Despite pleading not guilty to all charges last February, Carrillo and the prosecution initiated plea negotiations to avoid a trial. Judge Azrack has granted several extensions for these discussions. The prosecution has stated it will not seek the death penalty, leaving a maximum sentence of life imprisonment for Carrillo.
Carrillo, who inherited leadership of the Juรกrez Cartel after his brother Amado Carrillo, "El Seรฑor de los Cielos," died, faces serious charges. These include continuing criminal enterprise, conspiracy to import cocaine into the United States, using firearms in drug offenses, and money laundering. He and associate Rafael Caro Quintero were extradited from Mexico in February 2025 to face these charges in the U.S.
productivos
Originally published by El Universal in Spanish. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.